CymaBay Therapeutics (CBAY) Surges Amid Possible Re-initiation of Phase 3 Study Of Seladelpar

Unlike Moderna, Pfizer, and Vaxart CymaBay Therapeutics (NASDAQ: CBAY) rockets due to other studies and researches that test existing drugs on the seriously fatal diseases. A potent and selective peroxisome proliferator, seladelpar which is activated receptor delta (PPARδ) agonist that has demonstrated anti-cholestatic and anti-inflammatory effects in clinical studies for PBC. So, this drug has demonstrated efficacy, safety, and became well-tolerated in Phase 2 study on patients with primary biliary cholangitis (PBC).

After announcing the next study to confirm the potential of seladelpar CBAY has risen 50% on increasing daily volume that may exceed average volume by 10 fold.

If the upcoming phase 3 study delivers positive results CBAY may rocket till $20 by the aid of short term traders.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life